The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
Andrea Gallamini,
Sally F. Barrington,
Alberto Biggi,
Stephane Chauvie,
Lale Kostakoglu,
Michele Gregianin,
Michel Meignan,
George N. Mikhaeel,
Annika Loft,
Jan M. Zaucha,
John F. Seymour,
Michael S. Hofman,
Luigi Rigacci,
Alessandro Pulsoni,
Morton Coleman,
Eldad J. Dann,
Livio Trentin,
Olivier Casasnovas,
Chiara Rusconi,
Pauline Brice,
Silvia Bolis,
Simonetta Viviani,
Flavia Salvi,
Stefano Luminari,
Martin Hutchings
Affiliations
Andrea Gallamini
Research and Medical Innovation Department, Centre Antoine Lacassagne, Nice, France
Sally F. Barrington
Division of Imaging, King’s College London, PET Centre, Guy’s & St. Thomas’ Hospital, London, UK
Alberto Biggi
Nuclear Medicine Department, PET Center, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
Stephane Chauvie
Medical Physics Unit, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy
Lale Kostakoglu
Department of Radiology, Division of Nuclear Medicine, Mount Sinai Medical Center, New York, NY, USA
Michele Gregianin
Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
Michel Meignan
Nuclear Medicine Department, Centre Universitaire Hospitalier Henri Mondor, Creteril, Paris, France
George N. Mikhaeel
Clinical Oncology Department. Guy’s & St. Thomas’ Hospital, London, UK
Annika Loft
PET & Cyclotron Unit, Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, Denmark
Jan M. Zaucha
Department of Oncology, Gdynia Oncology Centre & Department of Propedeutic Oncology, University of Gdansk, Poland
John F. Seymour
Haematology Department, Peter MacCallum Cancer Centre, Melbourne, and University of Melbourne, Parkville Victoria, Australia
Michael S. Hofman
Center for Cancer Imaging Peter Mac Callum Cancer Center, Melbourne, Australia
Luigi Rigacci
Hematology Department, University of Florence, Careggi Hospital, Italy
Alessandro Pulsoni
Cellular Biotechnology and Hematology Department, Sapienza University, Rome, Italy
Morton Coleman
Hematology-Oncology Division, Center for Lymphoma & Myeloma, Weill Cornell Medical Center, New York, NY, USA
Eldad J. Dann
Department of Hematology & Bone Marrow Transplantation; Rambam Medical Center, Haifa, Israel
Livio Trentin
Hematology Department, University of Padua, Italy
Olivier Casasnovas
Hematology Department, Hopital Le Bocage, Dijon, France
Chiara Rusconi
Hematology Department - Niguarda Ca’ Granda Hospital, Milan, Italy
Pauline Brice
Hematology Department Centre Hospitalier Universitaire St. Louis, Paris, France
Silvia Bolis
Hematology Department, S. Gerardo University Hospital, Monza, Italy
Simonetta Viviani
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Flavia Salvi
Department of Hematology, SS Antonio e Biagio Hospital, Alessandria, Italy
A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of ‘interim’ positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point scale for the interpretation of interim positron emission tomography scan. Two hundred and sixty patients with newly diagnosed Hodgkin lymphoma were enrolled. Fifty-three patients with early unfavorable and 207 with advanced-stage disease were treated with doxorubicin, bleomycin, vinblastine and dacarbazine ± involved-field or consolidation radiotherapy. Positron emission tomography scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. An international panel of six expert reviewers independently reported the scans using the Deauville five-point scale, blinded to treatment outcome. Forty-five scans were scored as positive (17.3%) and 215 (82.7%) as negative. After a median follow up of 37.0 (2–110) months, 252 patients are alive and eight have died. The 3-year progression-free survival rate was 83% for the whole study population, 28% for patients with interim positive scans and 95% for patients with interim negative scans (P
